RAPIVAB (Peramivir) Patent Expiration, LOE Window & CMS Spending

RAPIVAB (Peramivir) by Biocryst: FDA Orange Book LOE 2027-05-07, 0 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBiocryst
FDA Application & PathwayN206426 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2027-05-07
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel